Golimumab (CNTO-148) is a potent humanized anti-TNFα IgG1κ monoclonal antibody with anti-inflammatory and anticancer activity. It inhibits the production of IL-6 and IL-1β, induces apoptosis, and can be used to prevent inflammation and destruction of cartilage or bone. This makes Golimumab valuable for studying rheumatoid arthritis and cancer.

Inducing reductions in the viability of transmembrane TNFα–expressing cells, Golimumab (CNTO-148) (0.1-10 μg/mL; 24-72 hours; transmembrane TNFα–transfected Jurkat cells) [1].Inducing apoptosis, increasing the levels of active caspase-3, and inducing apoptotic DNA fragmentation, Golimumab (CNTO-148) (10 μg/mL; 48 hours; transmembrane TNFα–transfected Jurkat cells) [1].

Golimumab (CNTO-148), administered intraperitoneally at doses of 1-10 mg/kg daily for 4 weeks in the Tg197 transgenic mouse model, relieves TNFα-induced arthritis in a mouse model of humans [3].Golimumab (CNTO-148), administered intravenously at a dose of 24 mg/kg daily for 7 days in Swiss-albino healthy male mice, inhibits oxidative stress, apoptotic cell death, and inflammatory response, thereby improving renal function. Golimumab reduces all markers of kidney injury and attenuates cell death [3].

Human

Monoclonal

Unconjugated